Clinical Trials
11 trialsNCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT04205838 2026-02-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT05153330 2025-07-03
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
Phase 1 Terminated
NCT04436120 2024-12-03
TRANSLATE
Pfizer
Phase NA Terminated
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04005144 2022-10-17
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
University of California, San Francisco
Phase 1 Terminated
NCT03727841 2022-07-27
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00108056 2019-12-05
Enzastaurin to Treat Recurrent Brain Tumor
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01778530 2015-10-07
TRC105 for Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00393094 2012-07-13
Bevacizumab and Irinotecan to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00171925 2012-04-11
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Novartis
Phase 3 Terminated